B Riley FBR

Concerned About The Election? Take Profits Off The Table Now, Strategist Says

Novavax Analyst Sees Leading Contender In Coronavirus Vaccine Race

Mastercraft Boat Rides Upgrade After Analyst Is 'Increasingly Confident' Demand Is Intact

Novavax Analyst Sees Leading Contender In Coronavirus Vaccine Race

Mastercraft Boat Rides Upgrade After Analyst Is 'Increasingly Confident' Demand Is Intact

Novavax Analysts Say CEPI Funding 'Speaks Volumes' About Coronavirus Vaccine Development

Spectrum Pharma Analyst Says Sell-Off May Have Been Overdone

Novavax Analysts Say CEPI Funding 'Speaks Volumes' About Coronavirus Vaccine Development

Spectrum Pharma Analyst Says Sell-Off May Have Been Overdone

Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption

The Street Debates What To Do With Yelp Stock After Q4 Beat

B Riley FBR Recent News

The Midterm Election: What 3 Pros Expect

Recent Assembly Biosciences Weakness Provides Attractive Entry Point, B Riley FBR Says In Upgrade

FBR: Novavax Looks Healthy Ahead Of Catalysts

Ahoy, Upside Ahead: B Riley FBR Out Bullish On 3 Shipping Stocks

Analysts React To Weight Watcher's Q2 Earnings

Pluristem Therapuetics, Rexahn Pharma Are Biotech Winners, B Riley FBR Says In Bullish Initiation

Columbia Sportswear Downgraded Ahead Of Q2 Print

Farmland Partners Loans Are 'Concerning, But Immaterial,' Analyst Says In Upgrade

Broadcom Shares Plummet After Wall Street Questions Sudden Acquisition Strategy

Analyst: Tetra Technologies Is An 'EBITDA Engine'

Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run

B. Riley FBR: 3 Reasons To Buy Alimera Sciences

3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy

Deciphera Pharma Hit With Sell-Side Downgrade On Valuation After 50% Gain

HomeStreet Cost Cuts Should Result In Higher 2019 Earnings, Analyst Says In Upgrade

Ramaco Resources Holds 25% Upside Potential, Analyst Says In Bullish Initiation

Analysts Applaud Intel's Q1 Beat-And-Raise, Say Delay In 10-Nanometer Chips A Negative

Analyst: Clementia Has Potential To Reach Unmet Market For Rare Bone Disease

Dicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral Initiation

After Nvidia Analyst Day, Wall Street Talks AV Testing, Artificial Intelligence, GPUs

Main Street Capital Has The Ingredients For Superior Economic Return, Says B Riley FBR

JD Sports' $588-Million Finish Line Purchase Is Positive For Both Companies

BB&T Should Trade At Premium To Other Large-Cap Banks, Says B Riley FBR